Approaching a major inflection point?29 Jul 2020 20:04
Part of a research note from Turner Pope:
Having recently put thenecessary financial resources in place, Avacta nowappears positionedto reach a number of major inflection points. While timingremains of the essence for anyCOVID-19 therapeutic development, the broader research opportunity that now also encompasses potential application for future global pandemics could create exceptional long-term value. The wider ambition of the JV to also control infectious respiratory disease outbreaksthat already commandmulti-billiondollarmarkets furtherhighlights the development potential offered throughAffimer molecules.
Today’s news covers just one of anumber ofambitious and rapidly developing projects Avacta presently has underway, all of which address areas of major growth potential. Although,given the development stage and rapidly moving background, it is not presently possible to award specific, high confidencevalue to any of these, successful delivery could further multiply Avacta’s current market valuation in the relatively near-term.